NEU-002

About Onchilles Pharma

Onchilles Pharma is a private, preclinical-stage biotech leveraging its proprietary ELANE pathway platform to develop next-generation, selective cytotoxic therapies. The company's approach targets elevated histone H1, a vulnerability shared across cancer types, aiming to deliver potent tumor killing without damaging immune cells. With a pipeline focused on intratumoral and intravenous biologics for multiple solid tumors, Onchilles is preparing for initial clinical trials in 2025/2026, positioning itself at the intersection of targeted cytotoxicity and immunotherapy.

Therapeutic Areas